Ppi rebounding
- Replies 10
- Views 7.2k
- Created
- Last Reply
Top Posters In This Topic
-
Tiffykins 2 posts
-
LAN2k 2 posts
-
stcyt 2 posts
-
ouroborous 1 post
Popular Days
Featured Replies
Join the conversation
You can post as a guest; create a free account to track replies, follow topics, and be part of the largest weight loss surgery community.
I have been reading so many people on here afraid of going off their PPI's and then when they do the acid is still there. I actually remembered hearing an article a couple of years ago on NPR about PPI rebounding and went online to see if I could find this information anywhere. I found an article and thought I would post it for you guys. Hope its helpful. But the basically when you come off the PPI's the stomach acid rebounds and produces, at least at first, more than you started with. So I would think it's important to give going off the PPI more time before you go running back to save yourself from the burning.
How to Survive "Acid Reflux Rebound"
PPI drugs are supposed to be used for a restricted period of time, however most patients continue their use indefinitely. Not only do patients abuse these drugs, but also the physicians who prescribe them. There are no studies regarding the long term use of PPIs. One has to question whether their prolonged use is really safe. Fortunately, there are natural ways to survive "acid reflux rebound".
There are many people who suffer from acid reflux and want to get off the proton pump inhibitor drugs (PPI drugs). The main action of this group of pharmaceuticals is the long acting reduction of gastric acid production. These include Prevacid, Prilosec, Nexium and Protonix.
These drugs are convenient to use and can be initially useful, but many find that the side effects outweigh the benefits. When it comes to quitting them, one will find that it is not so easy.
PPI drugs are supposed to be used for a restricted period of time, however most patients continue their use indefinitely. Not only do patients abuse these drugs, but also the physicians who prescribe them. Unfortunately, there are no studies regarding the effects of the long term use of these drugs. One has to question whether the prolonged use of PPI drugs is really safe.
We do know that by reducing the production of stomach acid, the proper digestion and assimilation of food is restricted. Are chronic users of these drugs suffering from a form of malnutrition? It is important to keep in mind that stomach acid also keeps potentially dangerous intestinal bacteria in check. So what may seem to be acid reflux utopia, in reality may be acid reflux hell.
When one stops these drugs, after prolonged use, the acid pumps turn on again and come back with a vengeance producing more acid than they did before. This is referred to as "acid reflux rebound". This is often such a terrible and frightening experience that most people become quickly discouraged and immediately get back on the drugs. This "catch 22" situation has proven to be a virtual gold mine for the pharmaceutical companies, who make billions of dollars in profits each year.
It is a horrible position to be in. You know you want to quite these drugs. They stop working and you are instructed to double the dose. You make an effort to stop, but it all backfires on you. Your throat burns like its on fire and your doctor tells you that if you don?t take the drugs you may develop esophageal cancer. Who wouldn?t be frightened?
Now for the good news; there are non-pharmaceutical things that one can do to survive "acid reflux rebound" and get back on the right track.
At this point there is most likely damage to the esophagus. One cannot hope to improve until the esophagus is well again.
In order to heal the esophageal damage, there are a few things to be considered. First and foremost one must temporarily change their diet. By now everyone should be aware of what foods and beverages trigger their acid reflux. Replace these offending foods with mild, easy to digest foods.
Instead of a slice of pizza with acidic tomato sauce, have a salad. Substitute that morning cup of coffee with a cup of tea. Have a glass of white instead of red wine with dinner. It?s just a matter of common sense, but these changes are necessary during the acid reflux recovery period.
In order to defeat the acid reflux syndrome, one must attempt to become as alkaline as possible. Anything which has an acidic effect on the body should be eliminated. Smoking is perhaps the most acidic thing one can do. Eating too much at one time causes an over production of stomach acid. Aerobic exercise actually causes the body to become more alkaline in nature.
Drinking copious amounts of clean fresh Water will help flush out the acidic toxins which accumulate in the body. A body which is properly hydrated is rarely acidic in nature. A glass of water after a meal is a good idea, but drinking much of anything with meals is counter productive. This dilutes the digestive fluids, causing the stomach to produce more acid.
Believe it or not, chewing gum between meals is beneficial. Chewing produces saliva which is very alkaline. Chewing gum after meals puts more alkalinity in the stomach to counteract the over production of acid.
There are many natural ingredients found in grocery and health food stores, which can help during the acid reflux recovery period. Herbs, such as marshmallow and slippery elm have wonderful healing properties. Licorice, natural honey and aloe vera juice can sooth the esophageal lining and assist in the healing process.
There are very few cases of acid reflux which can?t be successfully treated if one understands what causes this condition. Simple things like eating slowly and chewing food thoroughly, in a pleasant relaxed atmosphere, can reduce ones chances of having acid reflux.
We do not have to be prisoners of this drug oriented "acid reflux rebound" effect. It is unfortunate that most doctors rely on pharmaceuticals as the only solution to the acid reflux condition.
With a little education regarding the causes of acid reflux and the knowledge of natural medicine, one can survive "acid reflux rebound" and go on to live a normal life. We are at the brink of a new era where the patient must sometimes also be the healer.
? 2007 Wind Publishing
By Crystal Phend, Staff Writer, MedPage Today
Published: July 02, 2009
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
Earn CME/CE credit
for reading medical news
SAN FRANCISCO, July 2 -- Proton-pump inhibitors may cause or aggravate the very acid-reflux symptoms they're used to treat, according to a randomized trial. Action Points
Explain to interested patients that the study supported the hypothesis that PPI treatment induces compensatory mechanisms that result in rebound acid secretion after discontinuation of therapy.
Note that the study included only asymptomatic, healthy individuals, who may differ from symptomatic patients in important ways.
After a two-month course of esomeprazole (Nexium), 44% of asymptomatic, healthy volunteers had clinically significant heartburn, acid reflux, or dyspepsia, compared with 15% who had taken placebo (P<0.001), according to researchers led by Peter Bytzer, MD, PhD, of Copenhagen University and K?ge University Hospital.
This apparent rebound acid secretion, to a point above baseline levels, could lead to PPI dependence, the group reported in the July issue of Gastroenterology.
Treatment guidelines support the typical primary care practice of initiating a trial of PPI treatment empirically for dyspeptic symptoms, the researchers said.
However, up to a third of these patients keep taking the drug in the absence of symptoms, with physicians in some studies reporting that withdrawal or dose reduction in long-term PPI use is hard to achieve.
"Thus, patients with ambiguous symptoms that are not truly acid related may be prescribed a PPI empirically, but may find it difficult to withdraw from therapy because of the development of true acid-related symptoms," the researchers said.
The hypothesis, though controversial, has been that PPIs perpetuate symptoms and necessitate their continued long-term use.
The proposed mechanism for this so-called rebound acid hypersecretion is that elevated gastric pH caused by blockage of the proton-pumps stimulates compensatory mechanisms leading to increased capacity to stimulate gastric acid secretion.
Dr. Bytzer's results supported this theory. Symptoms in the PPI group continued, even in the final week of the study, after gastric acid suppression measured by plasma gastrin levels had normalized, with sustained elevation in the acid secretory capacity reflected by chromogranin A levels (P=0.02 at week 12 versus baseline).
In an accompanying editorial, Kenneth E. L. McColl, MD, and Derek Gillen, MD, both of the University of Glasgow in Scotland, said the findings should challenge current "liberal" prescribing habits.
Among their recommendations:
Restrict PPI use to patients likely to derive benefit, such as those with symptoms accompanied by endoscopic evidence of erosive esophagitis or of increased esophageal acid exposure.
Limit the PPI trial to one or two weeks as a diagnostic test for possible acid-related symptoms to reduce the chance of inducing hyperacidity and associated symptoms.
Adopt a "step-up" approach rather than "step-down" from medications to lifestyle alterations and milder medications such as antacids or alginates.
Inform patients about rebound acid hypersecretion and its potential effects as part of the discussion about side effects and safety.
To prove that the "acid rebound" symptoms were not simply a relapse of symptoms from underlying disease, Dr. Bytzer's group conducted a double-blind, placebo-controlled trial in 120 healthy volunteers without any prior acid-related disease, symptoms, or treatment.
These participants were randomized to receive 12 weeks of placebo or eight weeks of esomeprazole 40 mg/d, followed by four weeks of placebo.
None of the symptoms reported on the Gastrointestinal Symptom Rating scale questionnaire patients filled out each week was different between groups through week eight.
But after the PPI group discontinued therapy in week nine, their dyspepsia and reflux syndrome scores on the gastrointestinal-specific scale climbed in comparison with the placebo group.
For weeks nine through 12, the esomeprazole group had significantly higher overall mean combined dyspepsia and reflux syndrome scale scores (1.35 versus 1.12, P<0.001) and isolated reflux syndrome scale scores (1.36 versus 1.13, P=0.009).
The only individual symptoms with elevated incidence at week 12 among PPI-group participants compared with placebo-treated subjects were heartburn (difference 12.1%, P=0.006), acid regurgitation (difference 10.3%, P=0.013), and dyspepsia (difference 12.1%, P=0.017).
Other symptoms included on the questionnaire, such as indigestion, constipation, and diarrhea, were not different between groups.
The typically mild to moderately severe reflux symptoms showed up within the first two weeks after discontinuation of esomeprazole for the majority of patients.
The duration of the rebound symptoms, however, was unclear because they were still present at the end of the monitoring period four weeks after discontinuing the treatment.
The researchers acknowledged that the symptoms seen in these healthy individuals could differ from those in symptomatic patients.
"On the other hand, rebound acid hypersecretion could be even more relevant in patients with reflux disease or other acid-related disorders," they said, if those patients find it difficult to quit PPIs because of rapid recurrence of symptoms aggravated or even provoked by rebound acid hypersecretion.
The study was funded by the Danish Medical Research Council, K?benhavns Amts Research Foundation, and Region Sj?llands Research Foundation. The study medication and placebo were provided by AstraZeneca.
Dr. Bytzer reported conflicts of interest with manufacturers of proton-pump inhibitors -- AstraZeneca, Wyeth, Nycomed, and Eisai. A co-author reported conflicts of interest with Wyeth.
The editorialists reported no conflicts of interest.